Bivalent Human Papillomavirus Vaccine Effectiveness in a Japanese Population: High Vaccine-Type–Specific Effectiveness and Evidence of Cross-Protection-Reference-Cited by-同舟云学术

Bivalent Human Papillomavirus Vaccine Effectiveness in a Japanese Population: High Vaccine-Type–Specific Effectiveness and Evidence of Cross-Protection

Published:2018-10-09 Issue:3 Volume:219 Page:382-390
ISSN:0022-1899
Container-title:The Journal of Infectious Diseases
language:en
Short-container-title:

Author:

Kudo Risa¹,Yamaguchi Manako¹,Sekine Masayuki¹,Adachi Sosuke¹,Ueda Yutaka²,Miyagi Etsuko³,Hara Megumi⁴,Hanley Sharon J B⁵,Enomoto Takayuki¹

Affiliation:

1. Department of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan

2. Departments of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Japan

3. Department of Obstetrics and Gynecology, Yokohama City University School of Medicine, Yokohama, Japan

4. Department of Preventive Medicine, Faculty of Medicine, Saga University, Saga, Japan

5. Department of Obstetrics and Gynecology, Hokkaido University Graduate School of Medicine, Sapporo, Japan

Funder

Health and Labor Sciences Research

Japanese Agency for Medical Research and Development

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Immunology and Allergy

Link

http://academic.oup.com/jid/article-pdf/219/3/382/27442399/jiy516.pdf

Reference36 articles.

1. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis;Drolet;Lancet Infect Dis,2015

2. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study;Kavanagh;Lancet Infect Dis,2017

3. Very low prevalence of vaccine human papillomavirus types among 18- to 35-year old Australian women 9 years following implementation of vaccination;Machalek;J Infect Dis,2018

4. Epidemiologic classification of human papillomavirus types associated with cervical cancer;Muñoz;N Engl J Med,2003

5. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial;Wheeler;Lancet Oncol,2012

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How has post-implementation surveillance of high-coverage vaccination with HPV16/18-AS04 vaccine in England added to evidence about its cross-protective effects?;Vaccine;2024-10

2. HPV Vaccine Issues in Japan: A review of our attempts to promote the HPV vaccine and to provide effective evaluation of the problem through social-medical and behavioral-economic perspectives;Vaccine;2024-09

3. Vaccine Effectiveness Of Bivalent HPV Vaccination Against Genital HPV Of A Catch-Up Campaign And 12 Years Routine Vaccination For Girls-Only: A Biennial Repeated Cross-Sectional Study;2024-07-19

4. Questionnaire survey on cervical cancer screening and HPV awareness among patients at a local cancer center in Japan;BMC Women's Health;2024-07-16

5. Estimation of self‐funded human papillomavirus vaccine recipients from Japan's previously assumed “unvaccinated generation”;Cancer Science;2024-07-11